Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat.
Alterations in general characteristics and morphology of the heart, as well as changes in hemodynamics, myosin heavy chain isoforms, and beta-adrenoceptor responsiveness, were determined in Sprague-Dawley rats at 1, 2, 4, 8, and 16 wk after aortocaval fistula (shunt) was induced by the needle technique. Three stages of cardiac hypertrophy due to volume overload were recognized during the 16-wk period. Developing hypertrophy occurred within the first 2 wk after aortocaval shunt was induced and was characterized by a rapid increase of cardiac mass in both left and right ventricles. Compensated hypertrophy occurred between 2 and 8 wk after aortocaval shunt where normal or mild depression in hemodynamic function was observed. Decompensated hypertrophy or heart failure occurred between 8 and 16 wk after aortocaval shunt and was characterized by circulatory congestion, decreased in vivo and in vitro cardiac function, and a shift in myosin heavy chain isozyme expression. However, the positive inotropic effect of isoproterenol was augmented at all times during the 16-wk period. Characterization of beta-adrenoceptor binding in failing hearts at 16 wk revealed a significant increase in beta(1)-receptor density, whereas beta(2)-receptor density was unchanged. Consistent with this, basal adenylyl cyclase activity was significantly increased, and both isoproterenol- and forskolin-stimulated adenylyl cyclase activities were also increased. These results indicate that upregulation of beta-adrenoceptor signal transduction is a unique feature of cardiac hypertrophy and failure induced by volume overload.
Wang
Xi
X
Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, Winnipeg, Manitoba, Canada R2H 2A6.
Ren
Bin
B
Liu
Songyan
S
Sentex
Emmanuelle
E
Tappia
Paramjit S
PS
Dhalla
Naranjan S
NS
D000818:Animals; D001158:Arteries / Q000503:physiopathology; D002303:Cardiac Output, Low / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology*; D006332:Cardiomegaly / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology*; D003326:Coronary Circulation; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006439:Hemodynamics; D006940:Hyperemia / Q000150:complications*; D007527:Isoenzymes / Q000378:metabolism; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D009200:Myocardial Contraction; D009206:Myocardium / Q000201:enzymology / Q000473:pathology; D009218:Myosins / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011943:Receptors, Adrenergic, beta / Q000378:metabolism
D007527:Isoenzymes; D011943:Receptors, Adrenergic, beta; D009218:Myosins; D007545:Isoproterenol